These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38231873)

  • 1. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.
    Maier CS; Eckert D; Laroux FS; Hew KM; Suleiman AA; Liu W; Mohamed MF
    Clin Pharmacol Drug Dev; 2024 May; 13(5):474-484. PubMed ID: 38231873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults.
    Mohamed MF; Qian Y; D'Cunha R; Hao S; Carcereri De Prati R; Levy GF; Hew K; Liu W
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):801-809. PubMed ID: 38410874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.
    Mohamed MF; Qian Y; D'Cunha R; Sligh T; Ferris LK; Eldred A; Levy GF; Hao S; Gannu S; Rizzo DG; Liu W; Jazayeri S; Sofen H; Carcereri De Prati R
    Clin Transl Sci; 2024 Jan; 17(1):e13682. PubMed ID: 38112262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial.
    Tyring S; Moore A; Morita A; Hong HC; Song IH; Eccleston J; Levy G; Mohamed MF; Qian Y; Wu T; Pan A; Hew K; Papp KA
    Clin Exp Dermatol; 2024 May; ():. PubMed ID: 38699939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
    Datta-Mannan A; Regev A; Coutant DE; Dropsey AJ; Foster J; Jones S; Poorbaugh J; Schmitz C; Wang E; Woodman ME
    Clin Pharmacol Ther; 2024 May; 115(5):1152-1161. PubMed ID: 38294091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
    Timmermann S; Hall A
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
    Svecova D; Lubell MW; Casset-Semanaz F; Mackenzie H; Grenningloh R; Krueger JG
    J Am Acad Dermatol; 2019 Jul; 81(1):196-203. PubMed ID: 30926369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.
    Asimus S; Palmér R; Albayaty M; Forsman H; Lundin C; Olsson M; Pehrson R; Mo J; Russell M; Carlert S; Close D; Keeling D
    Br J Clin Pharmacol; 2020 Jul; 86(7):1398-1405. PubMed ID: 32067249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
    Bruin G; Loesche C; Nyirady J; Sander O
    J Clin Pharmacol; 2017 Jul; 57(7):876-885. PubMed ID: 28273356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
    Li Q; Qiao J; Jin H; Chen B; He Z; Wang G; Ni X; Wang M; Xia M; Li B; Chen R; Hu P
    Front Pharmacol; 2022; 13():966176. PubMed ID: 36052126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
    Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.
    Berstein G; Zhang Y; Berger Z; Kieras E; Li G; Samuel A; Yeoh T; Dowty H; Beaumont K; Wigger-Alberti W; von Mackensen Y; Kroencke U; Hamscho R; Garcet S; Krueger JG; Banfield C; Oemar B
    Clin Exp Dermatol; 2021 Jan; 46(1):122-129. PubMed ID: 32767679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A; Othman AA
    J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.
    Tham LS; Tang CC; Choi SL; Satterwhite JH; Cameron GS; Banerjee S
    J Clin Pharmacol; 2014 Oct; 54(10):1117-24. PubMed ID: 24752880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
    Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
    Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.